+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Psoriasis Treatment Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 160 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797922
Description Jump to:
The global psoriasis treatment market value was USD 26.13 billion in 2022, driven by the increasing prevalence of psoriasis across the globe. The market size is anticipated to grow at a CAGR of 9.23% during the forecast period of 2023-2031 to achieve a value of USD 57.84 billion by 2031.

Psoriasis Treatment: Introduction

Psoriasis is a chronic autoimmune skin disease characterized by the rapid build-up of skin cells, leading to scaling, inflammation, and redness. It affects people of all ages and can vary in severity from mild to severe. Psoriasis treatment aims to reduce inflammation, slow down the growth of skin cells, and alleviate symptoms. Treatment options include topical therapies, phototherapy, systemic medications, and biologic drugs, which are chosen based on the severity of the condition and individual patient needs.

The global psoriasis treatment market is experiencing significant growth due to factors such as the increasing prevalence of psoriasis, a growing awareness of the disease and its treatment options, and advancements in therapeutics. The introduction of novel biologic drugs and targeted therapies has revolutionized the treatment landscape, offering more effective and safer options for patients with moderate to severe psoriasis.

Psoriasis Treatment Market Scenario

The global psoriasis treatment market is poised for significant growth as the demand for effective treatments continues to rise. Factors such as the increasing prevalence of psoriasis, growing awareness of the disease and its treatment options, and advancements in therapeutics contribute to the market's expansion. The market is characterized by regional dynamics shaped by healthcare infrastructure, government support, and investment in research and development. However, challenges such as the high cost of biologic therapies, limited access to treatment in low- and middle-income countries, and potential side effects of certain medications may impact market growth.

North America: The largest market for psoriasis treatment, driven by factors such as advanced healthcare infrastructure, the presence of major pharmaceutical companies, and a robust research and development landscape.

Europe: The second-largest market, with increasing demand for psoriasis treatments due to a growing elderly population, government support, and an expanding healthcare sector.

Asia-Pacific: Expected to witness the highest growth rate due to factors such as a rapidly growing population, increasing prevalence of chronic diseases, and growing investments in healthcare infrastructure and research.

Psoriasis Treatment Market Segmentations

Market Breakup by Diagnosis Method

  • Blood Tests
  • Skin Prick Test
  • Patch Test
  • Biopsy
  • Others

Market Breakup by Treatment Type

Biologics Drugs

  • Apremilast
  • Atanercept
  • Infliximab
  • Adalimumab
  • Ustekinumab
  • Secukinumab
  • Ixekizumab
  • Guselkumab
  • Tildrakizumab
  • Certolizumab
  • Others

Systemic Drugs

  • Methotrexate
  • oriatane
  • Otezla
  • Sotyktu
  • Cyclosporin
  • Others

Phototherapy

  • Ultraviolet B (UVB)

Topical Drugs

  • Calcipotriene
  • Tazarotene
  • Calcineurin inhibitors
  • Roflumilast
  • Salicylic acid
  • Others
  • Others

Market Breakup by Type

  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Others

Market Breakup by Therapy Type

  • Monotherapy
  • Combination Therapy

Market Breakup by Route of Administration

Oral

  • Tablets
  • Capsules

Parentals

  • Intravenous
  • Intramuscular
  • Topicals
  • Others

Market Breakup by Drug Type

  • Over the Counter

Prescription

  • Branded
  • Generics

Market Breakup by Population Type

  • Childs

Adults

  • Male
  • Female

Geriatrics

  • Male
  • Female

Market by Breakup Treatment Channel

  • Public
  • Private

Market Breakup by End User

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Key Trends in the Psoriasis Treatment Market

Some key trends of the market are as follows:
  • Growing prevalence of psoriasis: The rising incidence of psoriasis worldwide is driving the demand for effective treatment options
  • Advancements in therapeutics: The introduction of biologic drugs and targeted therapies has improved treatment outcomes and increased the demand for these therapies
  • Increased awareness and patient support: Growing awareness of psoriasis and its treatment options, coupled with the availability of patient support programs, is driving market growth

Psoriasis Treatment: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Pfizer Inc
  • Abbvie Inc
  • Novartis AG
  • Amgen Inc
  • Boehringer Ingelheim International GmbH
  • Merck & Co Inc
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceuticals Industries Ltd
  • AstraZeneca
  • Ampio Pharmaceuticals Inc
  • Eli Lilly and Company
  • Novartis International AG
  • Sun Pharmaceuticals Industries Ltd
  • Stiefel Laboratories
  • UCB S.A
  • LEO Pharma
  • Cipla Inc
  • Rowan Bioceuticals
  • Glenmark Pharmaceuticals
  • Win-Medicare Pvt. Ltd
  • Sanofi S.A.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Psoriasis Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Psoriasis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Psoriasis Epidemiology (2016-2031)
5.3 Europe Psoriasis Epidemiology (2016-2031)
5.4 Asia-Pacific Psoriasis Epidemiology (2016-2031)
5.5 Latin America Psoriasis Epidemiology (2016-2031)
5.6 Middle East & Africa Psoriasis Epidemiology (2016-2031)
6 Global Psoriasis Treatment Market Overview
6.1 Global Psoriasis Treatment Market Historical Value (2016-2022)
6.2 Global Psoriasis Treatment Market Forecast Value (2023-2031)
7 Global Psoriasis Treatment Market Landscape
7.1 Psoriasis Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Psoriasis Treatment: Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Psoriasis Type
7.2.3 Analysis by Therapy Type
7.2.4 Analysis by Distribution Channel
7.2.5 Analysis by End User
8 Psoriasis Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Psoriasis Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Psoriasis Treatment Market Segmentation
11.1 Global Psoriasis Treatment Market by Diagnosis Method
11.1.1 Market Overview
11.1.2 Blood Tests
11.1.3 Skin Prick Test
11.1.4 Patch Test
11.1.5 Biopsy
11.1.6 Others
11.2 Global Psoriasis Treatment Market by Treatment Type
11.2.1 Market Overview
11.2.2 Biologics Drugs
11.2.2.1 Apremilast
11.2.2.2 Atanercept
11.2.2.3 Infliximab
11.2.2.4 Adalimumab
11.2.2.5 Ustekinumab
11.2.2.6 Secukinumab
11.2.2.7 Ixekizumab
11.2.2.8 Guselkumab
11.2.2.9 Tildrakizumab
11.2.2.10 Certolizumab
11.2.2.11 Others
11.2.3 Systemic Drugs
11.2.3.1 Methotrexate
11.2.3.2 Soriatane
11.2.3.3 Otezla
11.2.3.4 Sotyktu
11.2.3.5 Cyclosporin
11.2.3.6 Others
11.2.4 Phototherapy
11.2.4.1 Ultraviolet B (UVB)
11.2.5 Topical Drugs
11.2.5.1 Calcipotriene
11.2.5.2 Tazarotene
11.2.5.3 Calcineurin inhibitors
11.2.5.4 Roflumilast
11.2.5.5 Salicylic acid
11.2.5.6 Others
11.2.6 Others
11.3 Global Psoriasis Treatment Market by Type
11.3.1 Market Overview
11.3.2 Plaque Psoriasis
11.3.3 Psoriatic Arthritis
11.3.4 Others
11.4 Global Psoriasis Treatment Market by Therapy Type
11.4.1 Market Overview
11.4.2 Monotherapy
11.4.3 Combination Therapy
11.5 Global Psoriasis Treatment Market by Route of Administration
11.5.1 Market Overview
11.5.2 Oral
11.5.2.1 Tablets
11.5.2.2 Capsules
11.5.3 Parentals
11.5.3.1 Intravenous
11.5.3.2 Intramuscular
11.5.4 Topicals
11.5.5 Others
11.6 Global Psoriasis Treatment Market by Drug Type
11.6.1 Market Overview
11.6.2 Over the Counter
11.6.3 Prescription
11.6.3.1 Branded
11.6.3.2 Generics
11.7 Global Psoriasis Treatment Market by Population Type
11.7.1 Market Overview
11.7.2 Childs
11.7.3 Adults
11.7.3.1 Male
11.7.3.2 Female
11.7.4 Geriatrics
11.7.4.1 Male
11.7.4.2 Female
11.8 Global Psoriasis Treatment Market by Treatment Channel
11.8.1 Market Overview
11.8.2 Public
11.8.3 Private
11.9 Global Psoriasis Treatment Market by End User
11.9.1 Market Overview
11.9.2 Hospitals
11.9.3 Specialty Clinics
11.9.4 Homecare Settings
11.9.5 Others
11.10 Global Psoriasis Treatment Market by Distribution Channel
11.10.1 Market Overview
11.10.2 Hospital Pharmacy
11.10.3 Retail Pharmacy
11.10.4 Online Pharmacy
11.10.5 Others
11.11 Global Psoriasis Treatment Market by Region
11.11.1 Market Overview
11.11.2 North America
11.11.3 Europe
11.11.4 Asia Pacific
11.11.5 Latin America
11.11.6 Middle East and Africa
12 North America Psoriasis Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Psoriasis Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Psoriasis Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Psoriasis Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Psoriasis Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Pfizer Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Abbvie Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Novartis AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Amgen Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Boehringer Ingelheim International GmbH.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Merck & Co Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Sun Pharmaceutical Industries Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Teva Pharmaceuticals Industries Ltd.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 AstraZeneca
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Ampio Pharmaceuticals Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Eli Lilly and Company
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Novartis International AG
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Sun Pharmaceuticals Industries Ltd.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Stiefel Laboratories
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 UCB S.A.
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 LEO Pharma
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Cipla Inc.
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 Rowan Bioceuticals
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
23.19 Glenmark Pharmaceuticals
23.19.1 Financial Analysis
23.19.2 Product Portfolio
23.19.3 Demographic Reach and Achievements
23.19.4 Mergers and Acquisitions
23.19.5 Certifications
23.20 Win-Medicare Pvt. Ltd.
23.20.1 Financial Analysis
23.20.2 Product Portfolio
23.20.3 Demographic Reach and Achievements
23.20.4 Mergers and Acquisitions
23.20.5 Certifications
23.21 Sanofi S.A.
23.21.1 Financial Analysis
23.21.2 Product Portfolio
23.21.3 Demographic Reach and Achievements
23.21.4 Mergers and Acquisitions
23.21.5 Certifications
24 Psoriasis Treatment Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • Pfizer Inc.
  • Abbvie Inc.
  • Novartis AG
  • Amgen Inc.
  • Boehringer Ingelheim International Gmbh.
  • Merck & Co Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Astrazeneca
  • Ampio Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Novartis International AG
  • Sun Pharmaceuticals Industries Ltd.
  • Stiefel Laboratories
  • Ucb S.A.
  • Leo Pharma
  • Cipla Inc.
  • Rowan Bioceuticals
  • Glenmark Pharmaceuticals
  • Win-Medicare Pvt. Ltd.
  • Sanofi S.A.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages160
PublishedMay 2023
Forecast Period2023 - 2031
Estimated Market Value ( USD ) in 2023 $ 28.5 Billion
Forecasted Market Value ( USD ) by 2031 $ 57.8 Billion
Compound Annual Growth Rate9.2%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Psoriasis Global Market Report 2024 - Product Image

Psoriasis Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Plaque Psoriasis Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Plaque Psoriasis Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 96 Pages
  • Global
From
Psoriasis Treatment: Global Strategic Business Report - Product Image

Psoriasis Treatment: Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Psoriasis: Update Bulletin - Product Image

Psoriasis: Update Bulletin

  • Newsletter
  • Global
From
Global Psoriatic Arthritis Therapeutics Market Report and Forecast 2023-2031 - Product Image

Global Psoriatic Arthritis Therapeutics Market Report and Forecast 2023-2031

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.